HealthEquity, Inc. (NASDAQ:HQY) Given Average Rating of “Moderate Buy” by Brokerages

Shares of HealthEquity, Inc. (NASDAQ:HQY) have received a consensus rating of “Moderate Buy” from the thirteen ratings firms that are covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $111.8667.

A number of research analysts have weighed in on the company. Wells Fargo & Company set a $111.00 price target on HealthEquity in a research note on Monday, June 1st. BTIG Research reiterated a “buy” rating and issued a $115.00 target price on shares of HealthEquity in a research note on Friday, August 28th. KeyCorp reiterated an “overweight” rating on shares of HealthEquity in a research report on Tuesday, May 26th. Wall Street Zen raised shares of HealthEquity from a “hold” rating to a “buy” rating in a research note on Saturday, August 22nd. Finally, Royal Bank Of Canada increased their price objective on shares of HealthEquity from $100.00 to $108.00 and gave the stock an “outperform” rating in a report on Wednesday, June 3rd.

HealthEquity Stock Performance

NASDAQ HQY opened at $98.78 on Friday. HealthEquity has a 1-year low of $72.76 and a 1-year high of $107.62. The company has a market capitalization of $8.17 billion, a P/E ratio of 35.66, a PEG ratio of 1.56 and a beta of 0.22. The business has a 50 day moving average price of $99.21 and a 200 day moving average price of $88.55. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.99 and a quick ratio of 2.99.

HealthEquity (NASDAQ:HQY) last issued its quarterly earnings data on Thursday, August 27th. The company reported $1.24 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.19 by $0.05. The business had revenue of $350.73 million for the quarter, compared to the consensus estimate of $349.22 million. HealthEquity had a return on equity of 15.33% and a net margin of 17.36%.HealthEquity’s quarterly revenue was up 95.5% compared to the same quarter last year. HealthEquity has set its FY 2027 guidance at 4.660-4.730 EPS. Sell-side analysts expect that HealthEquity will post 3.93 EPS for the current fiscal year.

Insider Activity at HealthEquity

In other HealthEquity news, Director Adrian Dillon sold 7,632 shares of the stock in a transaction that occurred on Tuesday, August 25th. The shares were sold at an average price of $104.61, for a total transaction of $798,383.52. Following the transaction, the director owned 62,395 shares of the company’s stock, valued at $6,527,140.95. This trade represents a 10.90% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Fiore sold 2,470 shares of the firm’s stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $95.00, for a total transaction of $234,650.00. Following the completion of the transaction, the executive vice president owned 56,643 shares in the company, valued at $5,381,085. The trade was a 4.18% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 12,456 shares of company stock valued at $1,256,664 in the last ninety days. 1.60% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On HealthEquity

Several large investors have recently added to or reduced their stakes in HQY. Corient Private Wealth LP boosted its holdings in shares of HealthEquity by 8.6% in the 2nd quarter. Corient Private Wealth LP now owns 29,789 shares of the company’s stock valued at $2,691,000 after buying an additional 2,364 shares during the period. Amundi grew its stake in shares of HealthEquity by 33.6% in the 2nd quarter. Amundi now owns 90,327 shares of the company’s stock worth $8,158,000 after purchasing an additional 22,735 shares during the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new stake in shares of HealthEquity in the 2nd quarter worth approximately $2,619,000. California State Teachers Retirement System lifted its stake in HealthEquity by 8,679.7% during the second quarter. California State Teachers Retirement System now owns 8,832,754 shares of the company’s stock valued at $797,774,000 after purchasing an additional 8,732,150 shares during the last quarter. Finally, HB Wealth Management LLC boosted its holdings in HealthEquity by 70.2% during the second quarter. HB Wealth Management LLC now owns 4,671 shares of the company’s stock worth $422,000 after buying an additional 1,927 shares in the last quarter. 99.55% of the stock is currently owned by institutional investors.

About HealthEquity

HealthEquity, Inc (NASDAQ: HQY) is a leading administrator of consumer-directed health accounts and related benefit solutions in the United States. Founded in 2002 and headquartered in Draper, Utah, the company specializes in health savings accounts (HSAs) and offers complementary services such as flexible spending accounts (FSAs), health reimbursement arrangements (HRAs), COBRA administration and commuter benefits. Through its technology-driven platform, HealthEquity enables employers, health plans and individuals to streamline account management, improve cost transparency and encourage more informed healthcare spending.

Serving millions of members across all 50 states, HealthEquity leverages an open-architecture ecosystem that integrates with health plans, payroll providers and financial institutions.